> ANDS – Stirring up the immune system...uggggh, why is the CEO backing out, or yet, why do YOU think he is....if they can't resolve the dosing here what will be NVS' next move?<
NVS already made their move by inking a deal for HGSI’s Albuferon (#msg-11451787). Given that ANA975 is the drug most directly affected by the Albuferon program, I would say the probably is minuscule that the Albuferon deal was not based in large part on the ANA975 mishap.
I think ANDS’ CEO, Kleanthis Xanthopoulos, is leaving because the company is basically screwed. ANA975 is the crown jewel without the glitter.
By the way, EXEL’s CEO, George Scangos, who is ANDS’ Chairman, does not look good in all this. On the CC two weeks ago to announce Xanthopoulos’ departure, Scangos played the part of Ken Lay in assuring investors that Skilling’s, oops, I mean Xanthopoulos’ departure had nothing to do with any problems at ANDS.
Market Data 
Markets 
AI
